Dyne Therapeutics (DYN) Daily Trading Update
Dyne Therapeutics (DYN) closed the trading session on Thursday, 22 October 2026 at a price of USD 16.07 per share, representing a decline of ‑1.23 % compared with the previous 24‑hour period. The stock traded on several major exchanges and was valued at USD 3.0 bn in market capitalization.
24‑Hour Trading Summary
- Current price: USD 16.07
- 24‑hour volume: USD 28.8 mn worth of shares traded
- Total shares outstanding: 186.7 mn
- 52‑week range: Highest price USD 27.30 (12 August 2026); lowest price USD 14.00 (2 March 2026)
- Simple moving average (200 days): USD 19.36
- Month‑end change: Down ‑6.24 % from the previous month‑end value
Peer Performance (24‑Hour Basis)
| Ticker | 24‑Hour Change | Current Price (USD) | Market Cap (USD bn) | P/E Ratio |
|---|---|---|---|---|
| LMND (Lemonade) | ‑0.26 % | 45.28 | 3.5 | – |
| SKYW (Skywest) | +2.06 % | 94.25 | 3.6 | 9.2 |
| ACAD (Acadia) | ‑1.22 % | 20.19 | 3.5 | 9.24 |
| WBI (Waterbridge Infrastruc) | +2.95 % | 29.98 | 3.6 | 134.32 |
| VCYT (Veracyte) | +3.19 % | 46.22 | 3.6 | 32.09 |
Note: The P/E ratio for Lemonade is not disclosed in the provided data.
Recent Insider Transaction – Veracyte
On 20 October 2026, a Form 4 filing under the Securities Exchange Act of 1934 disclosed that director Bhanji Muna acquired 1,864 shares of Veracyte common stock under a Rule 10(b)(5)(1) plan. The acquisition increased Muna’s holdings to approximately 40,854 shares. The transaction was executed at a price reflecting the company’s market value at the time of purchase. No other executive or officer transactions were reported in the filing.
Company Overview – Dyne Therapeutics
- Industry: Biotechnology / Health Care
- Headquarters: Waltham, United States
- Business Focus: Development of muscle‑targeted therapies for serious medical conditions
- Exchange Listing: Nasdaq
- Website: www.dyne‑tx.com
This information summarizes the latest trading activity and recent corporate disclosures relevant to Dyne Therapeutics and its peer group.
